In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

3D echocardiographic assessment of right ventriculo-arterial coupling in mitral valve prolapse

Session Poster session 4

Speaker Laura Filippetti

Congress : EuroEcho 2019

  • Topic : imaging
  • Sub-topic : 3D Echocardiography
  • Session type : Poster Session
  • FP Number : P1405

Authors : LF Filippetti (Vandoeuvre les Nancy,FR), OH Huttin (Vandoeuvre les Nancy,FR), CV Venner (Vandoeuvre les Nancy,FR), RA Aubert (Vandoeuvre les Nancy,FR), YJ Juilliere (Vandoeuvre les Nancy,FR), CSS Selton-Suty (Vandoeuvre les Nancy,FR)

Authors:
LF Filippetti1 , OH Huttin1 , CV Venner1 , RA Aubert1 , YJ Juilliere1 , CSS Selton-Suty1 , 1Hospital Brabois of Nancy, cardiology - Vandoeuvre les Nancy - France ,

Citation:

Background: Both pulmonary artery pressure (PAP) and right ventricular (RV) function have shown their value in the prognostic evaluation of patients with mitral valve prolapse (MVP). Echocardiography which allows simultaneous pressure estimation and volume measurement by 3D allows an approach of arterial (Ea) and ventricular elastance (Emx) and of right ventriculo-arterial coupling (RVAC), usually derived from pressure-volume loops, and could be of interest in the assessment of the RV-PA unit. 

Methods: Thirty normal patients (group Nl, mean age 52.7±15.9) and 75 patients with stable MVP (mean age 52.4±15.4 (ns for age), 39 (group MVP1) with no or mild mitral regurgitation (MR) and 36 (group MVP2) with moderate to severe MR) underwent echocardiography including 3D RV acquisition. RV end-systolic volume (ESV), end-diastolic volume (EDV), stroke volume (SV) (mL) and ejection fraction (EF) (%) were obtained 3D echo (3DE) volumetric analysis (GE, EchoPac). mPAP was estimated from echo using Chemla’s formula (mPAP = 0.61 x sPAP + 2mmHg). Pulmonary artery effective elastance (Ea) was estimated as mPAP/SV (mmHg/mL), RV maximal end-systolic elastance (Emax) as mPAP/ESV (mmHg/mL), and RVAC as Ea/Emax. Ea, Emax and RVAC were compared between the 3 groups of patients using ANOVA.

Results: Mean LVEF was similar in the 3 groups. There was a significant differences in mPAP (Nl: 15.6±3.0; MVP1: 16.3±3.3; MVP2: 22.9±11.1, p=0.001). 

RVEDV (Nl: 81.3 ± 19.2; MVP1: 80.1 ± 22.0; MVP2: 96.1 ± 28.6, p=0.09), RVEF (Nl: 50.4 ± 4.4; MVP1: 49.3 ± 5.5; MVP2: 46.6 ± 6.6, p=0.02) and RVESV (Nl: 39.9 ± 9.8; MVP1: 40.8 ± 12.8; MVP2: 52.0 ± 19.5, p=0.01) were significantly different among the 3 groups. There was a non significant trend toward progressive increase in Ea (Nl: 0.41 ± 0.12; MVP1: 0.45 ± 0.15; MVP2: 0.53 ± 0.30, p=0.07) and E max (Nl: 0.42 ± 0.11; MVP1: 0.45 ± 0.17; MVP2: 0.53 ± 0.31, p=0.11) among the 3 groups but RVAC was not significantly different (Nl: 0.99 ± 0.17; MVP1: 1.04 ± 0.22; MVP2: 1.05 ± 0.37, ns). 

Conclusion: 3D echocardiography allows a complete analysis of the RV-PA unit and is able to reveal subtle changes in its equilibrium. Together with an increase in RV volumes and decrease in RVEF, our study reveals a progressive increase in arterial elastance in parallel with the severity of MR, compensated by an increase in ventricular elastance to maintain RV – PA coupling in those stable patients with MVP.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are